MMSI Merit Medical Systems Inc.

Merit Medical Executive Leadership Team Update

Merit Medical Executive Leadership Team Update

Joe Wright Appointed President

Expands Deep Bench of Leadership Team Talent; Supports “Continued Growth Initiatives” Program

SOUTH JORDAN, Utah, May 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced the appointment of Joe Wright as President, effective immediately. As President, Mr. Wright will be responsible for the oversight of Merit’s global commercial, marketing, and manufacturing operations.

Mr. Wright has been an instrumental part of the Merit team over the past 19 years. He most recently served as Chief Commercial Officer, where he led the development and expansion of Merit’s global commercial activities. Prior to that, he served as President of Merit’s International Division, leading Merit’s business units across APAC and the Americas, where he oversaw the development of Merit’s commercial strategy and led the expansion of the company’s international footprint, including the creation of Merit China in Beijing and the Merit Asia headquarters in Hong Kong.

“Investing in our people is a core part of the growth and profitability of our Continued Growth Initiatives Program,” said Fred P. Lampropoulos, Merit Medical’s Chairman and CEO. “Joe has been central to executing our strategic plan and positioning the company for continued success, including spearheading our commercialization efforts and overseeing significant international expansion, engineering the advanced capabilities of our renal therapies group, including the integration of the business and assets we acquired from AngioDynamics in 2023, and directing the development of our commercial excellence initiatives globally. He is a valuable member of our leadership team, and I look forward to continuing to work closely with him to improve the lives of patients and drive sustained value creation for our shareholders.”

“I am honored to take on the role of President at this important point in Merit’s journey,” said Mr. Wright. “I have been a part of this team for almost two decades and have developed a deep appreciation of Merit’s innovative technology, global access, unique and successful culture, alignment of values within the healthcare system and opportunities for growth. I look forward to advancing our CGI objectives, improving the profitability of our business, and investing in our future.”

Merit’s Board of Directors is continuing the process of identifying potential internal and external CEO candidates in preparation for the previously announced retirement of Mr. Lampropoulos at the end of 2025. The process is being overseen by Merit’s independent directors with the assistance of Korn Ferry, a leading executive search firm. Merit does not intend to provide further updates on the process until such time as a successor is designated.

ABOUT JOE WRIGHT

Joe Wright joined Merit Medical in 2005 and has served in a variety of roles, including most recently as Chief Commercial Officer, where he was responsible for leading the company’s overall commercial strategy. Prior to this, Mr. Wright served as President of Merit’s International Division, leading business units across APAC and the Americas. He also previously served as President of Merit Technology Group, overseeing Merit OEM, Merit Sensor and MCTec B.V. and as Vice President of Global Marketing. During his tenure, Mr. Wright oversaw the creation of Merit China in Beijing. He also established Merit Asia in Hong Kong, the company’s headquarters in Southeast Asia and expanded Merit’s presence with facilities and personnel in Australia, Brazil, Canada, India, Japan, Malaysia, South Korea, Taiwan and Vietnam. Before joining Merit, Mr. Wright held sales, marketing, and business development positions with Motorola and Micron. He holds Bachelor of Arts and Masters of Business Administration degrees from Columbia University.

ABOUT MERIT MEDICAL

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling more than 700 individuals. Merit employs approximately 7,000 people worldwide.

TRADEMARKS

Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.

CONTACTS

PR/Media Inquiries

Sarah Comstock

Merit Medical

| 

Investor Inquiries

Mike Piccinino, CFA, IRC

Westwicke - ICR

| 



EN
15/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Merit Medical Systems Inc.

 PRESS RELEASE

Merit Medical Launches the Prelude Wave Hydrophilic Sheath Introducer ...

Merit Medical Launches the Prelude Wave Hydrophilic Sheath Introducer with SnapFix Technology Thin-wall design with superior insertion and unique sheath-securement solution to support successful radial access procedures and may aid in reducing arterial spasm and occlusion SOUTH JORDAN, Utah, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced the US commercial release of the Prelude Wave™ Hydrophilic Sheath Introducer with SnapFix™ Securement Technology. The Prelude Wave is the latest innovation in Meri...

 PRESS RELEASE

Merit Medical Reports Second Quarter 2025 Results and Updates Full-Yea...

Merit Medical Reports Second Quarter 2025 Results and Updates Full-Year Guidance Highlights† Reported revenue of $382.5 million, up 13.2%Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 6.7%, respectivelyGAAP operating margin of 12.3%, compared to 13.6% in prior year periodNon-GAAP operating margin* of 21.2%, compared to 20.1% in prior year periodGAAP EPS $0.54, down 11.6%Non-GAAP EPS* $1.01, up 9.8%Free cash flow* generation of $89.1 million over first six months of 2025, up 8.1% year-over-yearAcquired Biolife Delaware, L.L.C. (“Biolife”), a manufacturer ...

 PRESS RELEASE

Merit Medical Names Martha Aronson as New President and Chief Executiv...

Merit Medical Names Martha Aronson as New President and Chief Executive Officer Fred Lampropoulos will continue to serve as Chairman of Merit’s Board of Directors Merit announces preliminary unaudited revenue for the quarter ended June 30, 2025 SOUTH JORDAN, Utah, July 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today the appointment of Martha Aronson as Merit’s new President and Chief Executive Officer, effective October 3, 2025. Fred P. Lampropoulos will remain as Chairman of the Board, President and CEO ...

 PRESS RELEASE

Merit Medical Systems To Announce Second Quarter 2025 Results On July ...

Merit Medical Systems To Announce Second Quarter 2025 Results On July 30, 2025 SOUTH JORDAN, Utah, July 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2025, after the close of the stock market on Wednesday, July 30, 2025. Merit plans to hold its investor conference call on the same day (Wednesday, July 30, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access ...

Merit Medical Systems Inc: 1 director

A director at Merit Medical Systems Inc sold 10,000 shares at 95.190USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch